News & Information | START In The News

July 29th, 2007
San Antonio Business Journal

START appoints new director of preclinical research

South Texas Accelerated Research Therapeutics (START) has added a third key player to the team overseeing its oncology drug development center.

START has hired Michael J. Wick as the group's director of preclinical research. He will join the staff on Sept. 3. He previously served as director of preclinical research at the Cancer Therapy & Research Center's Institute for Drug Development.

Wick joins a medical staff headed by Dr. Anthony Tolcher, who is the group's director of clinical research. Wick is also an instructor in the department of pharmacology at the University of Texas Health Science Center at San Antonio.

"Michael Wick brings an impressive track record of achievement to our cancer drug research team," Tolcher says. "His stature among the most respected oncology researchers in drug development further establishes this organization as one of the world's premier sites for development of innovative oncology drugs."

Earlier this week, START also hired Chris Takimoto as its director of pharmacology. Takimoto is the former director of pharmacology at CTRC's Institute for Drug Development.

START, which is affiliated with South Texas Oncology & Hematology, is in the process of building a 120,000-square-foot cancer center in the South Texas Medical Center. START will occupy 20,000 square feet in the building. The center should be completed by July 2008.